In regulated manufacturing environments, progress is defined by measurable, repeatable results — not by statements.

As the year comes to a close, it is time to take stock.

We chose to do so in the most concrete way possible: through the numbers that shaped IWT Pharma’s 2025.

These figures tell a story of consistency, operational discipline, and continuous improvement: the hallmarks of a reliable partner in the field of pharmaceutical cleaning and isolation technologies.

Quality, traceability, and operational reliability

Throughout 2025, our focus on process quality translated into tangible outcomes.

Compared to the previous year, customer complaints decreased by approximately 10%, confirming the effectiveness of our engineering, validation, and after-sales approach.

In parallel, we processed over 7,000 material certification and traceability records for pharmaceutical applications. Behind each document lies a controlled process, verified data, and full alignment with GMP expectations — an often invisible but essential foundation of regulated manufacturing.

This operational rigor was further reflected in factory acceptance activities, with:

• over 50 FATs completed on washing machines,
• multiple FATs on modular components and isolators,

supporting customers during critical project phases.

Investing in people and skills

Growth in regulated industries starts with people.
During the year, we welcomed over 30 new colleagues, with a strong focus on the next generation: more than half under 30 years old, and an increasing presence of women across technical and operational roles.

Training remained a priority, with over 4,400 hours of structured training delivered across the organization.

Through our Academy initiative, five young professionals were successfully integrated into the company, reinforcing our long-term commitment to competence development and knowledge continuity.

Innovation and evolution, beyond products

Innovation in 2025 took multiple forms.
We introduced two new solutions, each addressing specific needs in regulated environments:

• ASEPTICARE, our multipurpose isolator designed to support controlled aseptic handling, transfer, and decontamination workflows within GMP manufacturing environments,
• NEXUS, developed to enhance integration and process continuity within GMP systems.

At the same time, the year marked a broader evolution.
The launch of the Tecniplast Group, together with a complete brand redefinition, introduced a new visual identity and color palette — more closely aligned with pharmaceutical standards and with our positioning within an international industrial group.

This evolution was not cosmetic. It reflects a clearer, more structured way of presenting who we are and how we operate.

Expanding presence, entering new markets

Leveraging a well-established network of subsidiaries and agents, we strengthened our global footprint.
During 2025, we participated in more than 20 international events, conferences, and exhibitions, engaging directly with manufacturers, engineers, and decision-makers across multiple regions.

The year also marked a strategic step into a new market segment: ATMP manufacturing.
Advanced Therapy Medicinal Products introduce unique challenges in terms of containment, flexibility, and aseptic control — challenges that increasingly shape the future of pharmaceutical production.

Energy efficiency, sustainability, and isolation performance

Sustainability in 2025 was addressed through both operational initiatives and engineering choices.

From an environmental standpoint:

• over 90 kg of honey were produced by our on-site beehives,
• our photovoltaic system enabled the avoidance of approximately 37,000 kg of CO₂ emissions,
• corresponding to more than 1,100 equivalent trees planted.

In parallel, comparative analyses between open and closed systems highlighted significant differences in energy demand and environmental impact.
In ATMP-oriented isolation scenarios, closed isolation solutions — such as those enabled by ISOCELL — demonstrated the potential to significantly reduce overall energy consumption and emissions when compared to traditional open systems.

Based on annualized evaluations, these configurations can contribute to yearly CO₂ savings exceeding 70,000 kg, equivalent to more than 2,180 trees.
These figures confirm that engineering choices in isolation design influence not only compliance and process control, but also long-term sustainability.

Transparency, collaboration, and the IWT 3.0 vision

Beyond internal growth, we welcomed over 500 visitors to our facilities during the year.
Opening our doors to customers and partners reinforces transparency, collaboration, and trust — values that guide the way we work every day.

Looking ahead, 2026 will make on-site visits even more meaningful.
The development of the IWT 3.0 Pharma Building will significantly expand our operational capabilities, including:

• +115% operational space,
• +165% warehouse capacity,
• +120% pharma workshop areas,
• a new pharma production plant of approximately 8,900 m²,
• a 1,500 m² GMP metal workshop,
• and 700 m² dedicated to surface finishing operations.

This expansion will offer an even clearer view of our engineering standards, operational efficiency, and manufacturing approach.

Numbers that point forward

A year in numbers is never just about the past.
It is about understanding where consistency delivers results — and where to invest next.

For us, 2025 confirmed a clear direction:
engineering-driven solutions, measurable performance, and long-term partnerships built on reliability.